Phosphodiesterase 4 inhibitors

US7723348B2 · kind B2 · utility

Assignee

• Memory Pharmaceuticals Corporation · US

Inventors

• Allen Hopper · Glen Rock, US
• Robert F. Dunn · Towaco, US
• Erik Kuester · Rochester, US
• Richard Conticello · Ossining, US

Key dates

• Filing date: Apr 24, 2008
• Grant date: May 25, 2010
• Expiry date: Apr 24, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.